Bayer expands men’s healthcare portfolio

Licence agreement for innovative testosterone gel also covers emerging markets


Bayer Schering Pharma will develop and commercialise ProStrakan’s Tostrex® in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions.

December 04, 2008

Tostrex is indicated for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and biochemical analyses. Tostrex is a 2% testosterone gel presented in a canister with a metered pump.

“Adding Tostrex to our portfolio will strengthen our transdermal testosterone portfolio within the therapeutic business area of Men’s Healthcare in emerging markets,” said Jean-Philippe Milon, Head of Bayer Schering Pharma's Business Unit General Medicine.

Bayer already offers Levitra® for the treatment of erectile disfunction as well as testosterone therapies with Nebido® and Testogel® in the Men´s Healthcare portfolio. Levitra and Nebido are marketed in most countries globally exept the US and Testogel in Western Europe and Australia. Erectile Dysfunction (ED) and Testosterone Deficiency Syndrome (TDS) are men’s health problems that have both a physical and psychological impact on the patient.

News

Click here for further news about our partnering activities.
Page tools
.

open
close
http://www.bayerpharma.com/en/partnering/news/testosteron-gel.php

Copyright © Bayer Pharma AG